The rivalry between India and China in pharmaceuticals is the most consequential industrial contest of the next decade. It will […]

Patent litigation is where drug revenue is won or lost. For a blockbuster product generating $5 billion annually, a single

Every five years or so, the pharmaceutical industry rediscovers the patent cliff as though it is a new emergency. It

Every major pharmaceutical revenue event, from a blockbuster’s first generic competitor to a biosimilar’s delayed U.S. launch, traces back to

The single most valuable regulatory asset in the U.S. generic pharmaceutical industry is not a patent. It is the absence

Part I: The Architecture of Pharmaceutical Value — Patents as Financial Instruments What a Drug Patent Actually Is (And What

The $236 billion Loss of Exclusivity wave hitting between 2025 and 2030 is the most concentrated revenue erosion event in

Intellectual property has long been treated as a defensive asset — a legal shield erected around a discovery to keep

Introduction: The Paragraph IV Filing as Corporate Weapon A Paragraph IV certification is the most powerful offensive instrument in the